TECVAYLI + DARZALEX FASPRO
Relapsed/Refractory Multiple Myeloma
ApprovedApproved (FDA Mar 2026)
Key Facts
Indication
Relapsed/Refractory Multiple Myeloma
Phase
Approved
Status
Approved (FDA Mar 2026)
About johnson-and-johnson-innovative-medicine
Johnson & Johnson Innovative Medicine, established as a clarified entity in 2023 following the Kenvue spin-off, is a global pharmaceutical leader with a mission to transform healthcare through high-impact science. Its strategy integrates deep internal R&D with strategic business development to build a leading pipeline across oncology, immunology, neuroscience, and cardiopulmonary diseases. Recent achievements include the FDA approval of the first-in-class oral peptide ICOTYDE™ for psoriasis and the expansion of its multiple myeloma regimen, demonstrating its capacity for innovation and commercial execution within the J&J conglomerate.
View full company profileTherapeutic Areas
Other Relapsed/Refractory Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| Aplidin (plitidepsin) | PharmaMar | Approved (Conditional - AU) |
| Linvoseltamab | Regeneron | Phase 3 |
| Blenrep (belantamab mafodotin) | GSK | Phase III |
| CAR T-Cell Therapy Program | Dr. Reddy's Laboratories | Development |
| HDP-101 | Heidelberg Pharma | Phase I/IIa |
| inobrodib + Pd (InoPd) | CellCentric | Phase 1/2 |
| CT053 | CARsgen Therapeutics | Phase Ib/II |
| CT059 | CARsgen Therapeutics | Phase I |
| P-BCMA-ALLO1 | Poseida Therapeutics | Phase 1 |
| P-BCMA-101 | Poseida Therapeutics | Phase 1/2 |
| ABBV-383 | AbbVie | Phase 1 |
| bri-cel (BAY 2413334) | Bayer | Phase I |